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Objectives: The effectiveness of endoscopic screening for gastric cancer has been 
continually evaluated; however, only a few studies have reported its effectiveness. 
Notably morality reduction from cancer screening has not yet been rigorously evalu-
ated in survival analyses, but an important requirement for cancer screening is 
improving survival. We performed survival analysis for gastric cancer detected by 
endoscopic screening and compared the results with those of survival analysis for 
gastric cancer detected by radiographic screening and outpatients. MethOds: The 
subjects of our study were selected from gastric cancer cases registered in 4 cities 
in the Tottori Cancer Registry from 2001 to 2006. The target age group was defined 
as the age in which gastric cancer was diagnosed from 40 to 79 years. Follow-up 
was continued from the date of diagnosis to the time death from gastric cancer or 
up to December 31, 2011. The survival of 3 groups at 5 and 10 years were compared 
using the Kaplan-Meier method with the log-rank test. Results: There were 347 
subjects selected for endoscopic screening, 166 for radiographic screening, and 980 
as outpatients. The 5-year survival rates were follows: 91.2 ± 1.5% (95% CI: 87.6-93.8) 
for endoscopic screening, 84.3 ± 2.9% (77.7-89.1) for radiographic screening, and 66.0 
± 1.6% (62.8-68.9) for outpatients. The 10-year survival rates were follows: 88.5 ± 2.0% 
(83.9-91.9) for endoscopic screening, 80.1 ± 3.6% (71.9-86.2) for radiographic screen-
ing, and 64.6 ± 1.6% (61.3-67.6) for outpatients. The survival rates were significantly 
different in the 3 groups (P < 0.001). cOnclusiOns: The survival rate was higher 
for endoscopic screening than those for radiographic screening and outpatients. 
Since a high survival rate is mainly affected by lead–time bias, the effectiveness of 
endoscopic screening should be further evaluated in term of mortality reduction 
by conducting large-scale and reliable studies.
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Objectives: Screening for type 2 diabetes (DM) has peaked as a controversial issue 
given the publication of the recent Canadian guidelines and since the clinical trial 
evidence for the effectiveness of DM screening is lacking. MethOds: A two-step 
evidence-based analysis was performed: 1) narrative review of international guide-
lines 2) systematic review of primary studies. MEDLINE, EMBASE, CINAHL, Wiley 
Cochrane, and Centre for Reviews and Dissemination (2008-2012) were used to iden-
tify primary studies comparing the effectiveness of DM screening to usual care. 
Randomized controlled trials and observational studies meeting inclusion criteria 
were meta-analyzed and the quality of evidence was evaluated using GRADE. A 
cost analysis was developed using Ontario claims data and estimating the down-
stream health care costs in Canadian dollars of screening in Ontario. Results: Eight 
guidelines and six studies from 2,780 citations were identified. The recommenda-
tions for universal screening or screening for low to moderate risk individuals were 
heterogeneous, not shown for high or very high risk individuals. The guidelines 
consistently recommended screening for the latter. Screening was associated with 
a lower likelihood of retinopathy (RR: 0.54, 95% CI: 0.32-0.92) and lower absolute % 
HbA1c (MD: -0.32, 95% CI: -0.53, -0.11). Screening was not linked to increased anxi-
ety or false reassurance. One large RCT showed no beneficial effect of screening on 
long-term mortality outcomes. Two observational studies meta-analyzed showed 
no beneficial effect of screening for neuropathy and nephropathy. The quality of 
evidence was moderate to very low. Estimated cost savings is $150.4 million dollars 
using established parameters, with a range of cost savings as low as $16.7 up to 
$280.4 million dollars in sensitivity analysis. cOnclusiOns: Despite its widespread 
acceptance, the evidence for the long-term effectiveness of DM screening is lacking. 
Further clinical and cost analysis in Canada is needed for short-term outcomes to 
help clarify the issue.
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Objectives: To perform a systematic review to evaluate the quality of anticoagu-
lation control in outpatient pharmacist-managed anticoagulation services (PMAS) 
compared to routine medical care (RMC). MethOds: We searched MEDLINE, 
SCOPUS, EMBASE, IPA, CINAHL, Cochrane CENTRAL, with language restriction to 
English. Two authors independently reviewed each study and extracted data for all 
outcomes using a standardized form, with any disagreement resolved by a third 
author. The primary outcome was the quality of warfarin-related anticoagulation 
management using time in therapeutic range (TTR) as an indicator. Warfarin-related 
bleeding, thrombotic events and resource utilization were assessed as secondary 
outcomes. Results: Of 155 articles identified, 23 articles met the criteria for final 
review. Of these, three studies were RCTs and twenty were observational studies. 
Most studies were conducted between year 2000 to 2013 (N= 18, 78%), and study 
follow-up ranged from six to twelve months (N= 13, 57%). Among studies that 
reported patients’ age, the average age ranged from 46 to 80.5 years, and was simi-
lar between PMAS and RMC groups. The majority of patients were treated for atrial 
fibrillation and venous thrombosis. Quality of anticoagulation control was better in 
the PMAS group compared to RMC, as indicated by higher TTRs in the majority of 
the studies (N= 21, 91%). Clinical outcomes were also favorable in the PMAS group 
as evidenced by lower risk of major bleeding (N= 10 of 14, 71%) or thromboembolic 
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Objectives: Evidence from recent studies on statin treatment intensity for second-
ary prevention supports targeting lower low-density lipoprotein (LDL) levels through 
higher intensity statin treatment. This study aims to assess whether achievement 
of the lower LDL threshold is associated with a reduction in cardiovascular out-
comes. MethOds: Retrospective cohort study of adult members of a large health 
fund with pre-existing ischemic heart disease (IHD) treated with statins for at least 
one year during 2006-2010, and with a routine, fasting serum LDL test measures. The 
incidence of the composite Major Adverse Cardiac Events (MACE) was compared 
between three patient groups according to their achieved LDL: (> 70·1-100mg/dl 
(Moderate) vs. > 100·1-130mg/dl (High), and > 70·1-100mg/dl (Moderate) vs. ≤ 70mg/
dl (Low)). Results: Of 52,177 patients treated with statins, 11,647 had an achieved 
LDL (post-statin treatment) of 70mg/dl or below, 29,097 between 70.1-100mg/dl and 
11,433 between 100·1-130mg/dl. Mean follow-up time from achieved LDL to MACE 
was 3·6 years (±1·5), with 10,955 subjects incurring a MACE during follow-up. LDL 
levels 70·1-100mg/dl compared to 100-130mg/dl were associated with a significant 
8% reduction in the incidence of MACE (hazard ratio [HR]= 0·92 [95% CI, 0·88-0·97; 
p= 0·001]), while ≤ 70 mg/dl compared to 70·1-100mg/dl was not (HR= 0·98 [95% CI, 
0·93-1·03; p= 0·374]). Results remained consistent in propensity score–adjusted Cox 
regression, a sensitivity analysis, and in a sub-group analysis, with no demonstrated 
advantage in MACE outcomes for achieved LDL levels ≤ 70mg/dl. cOnclusiOns: 
Among a real-world population of IHD patients adherent to their statin treatment, 
achieving LDL levels below 100mg/dl is associated with significant clinical benefit, 
whereas no additional benefit is gained by achieving LDL levels below 70mg/dl.
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Objectives: To describe the natural history of metastatic prostate cancer in 
patients treated with androgen deprivation therapy (ADT) or orchiectomy in clini-
cal practice. MethOds: Newly diagnosed prostate cancer patients (2004-2010) 
treated with ADT/orchiectomy were identified from the Henry Ford Health System 
tumor registry. Patients were followed through July 31, 2012. Data on disease pro-
gression (rising prostate-specific antigen [PSA] and presence of metastases) were 
collected from medical records and automated data. Time from initial diagnosis 
to metastases was determined by Kaplan-Meier analyses. Results: We iden-
tified 702 patients; 58% ≥ 70 years and 50% African American; 56% of patients 
were initially diagnosed at stage II, 10% at stage III, 22% at stage IV, and 12% had 
missing/unknown stages. Three percent received orchiectomy; 97% received ADT. 
Comprehensive data on testosterone levels were not available. During follow-
up, an additional 8% of patients progressed to metastatic disease (N= 207): 52% 
(107) had evidence of postcastration disease progression (17% rising PSA, 28% 
presence of ≥ 2 new bone metastases, 55% met both criteria). Bone was the most 
common site, occurring in 74% of metastatic patients; 59% of metastatic patients 
developed bone mestastases to spine. Other metastatic sites included distant 
lymph nodes (12%), lung (8%), central nervous system (7%), and other (14%). Mean 
follow-up time was 3.8 years. Kaplan-Meier analysis indicated that by 5 years 
after initial diagnosis, 13% of stage II and 36% of stage III patients developed 
metastases. cOnclusiOns: While the incidence of cancer is routinely collected 
via registries, information on progression or recurrence is sparse. This study is 
one of few to present information on the natural history and disease progression 
of ADT/orchiectomy-treated prostate cancer in a clinical setting. In this study, we 
found 30% of patients were diagnosed with or progressed to metastatic disease. 
This assessment of medical need may inform future resource planning.
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Objectives: Objective To assess the diagnostic and clinical value of anti-mutated 
citrullinated vimentin (anti-MCV) antibody for rheumatoid arthritis (RA) via com-
paring with rheumatoid factors (RF) and anti-cyclic citrullinated peptide antibodies 
(anti-CCP). MethOds: Anti-MCV and anti-CCP were determined using enzyme-
linked immunosorbent assay (ELISA), and meanwhile, the RF was detected in 88 
patients with RA and 16 patients with other rheumatic diseases. Receiver operating 
characteristic (ROC) curve was operated to calculate the areas under the curve of RF, 
anti-CCP and anti-MCV, the max Youden indexes were also calculated to determine 
the optimum testing threshold and the corresponding sensitivity and specificity, 
the diagnostic significance of RF, anti-CCP and anti-MCV in RA were analyzed. The 
correlation of erythrocyte sedimentation rate (ESR) and anti-MCV, and C reactive 
protein (CRP) and anti MCV were evaluated by linear-regression analysis. Results: 
The areas under the curve of RF, anti-CCP and anti-MCV were 0.775, 0.847 and 
0.873, respectively. The max Youden indexes of RF, anti-CCP and anti-MCV were 
0.534, 0636 and 0.71, respectively, and the corresponding sensitivity and specificity 
were 78.4% and 75%, 63.6% and 100%, and 77.3% and 93.7%, respectively. A correla-
tion between ESR and anti-MCV antibody, and CRP and anti-MCV antibody levels 
was observed. cOnclusiOns: The sensitivity of anti-MCV is higher compared 
to anti-CCP and is comparable to RF, and its specificity is higher than that of RF. 
Consequently, anti-MCV can be served as a diagnostic index for RA and its expres-
sion is associated with disease activity of RA.
